JPS6229429B2 - - Google Patents
Info
- Publication number
- JPS6229429B2 JPS6229429B2 JP52017698A JP1769877A JPS6229429B2 JP S6229429 B2 JPS6229429 B2 JP S6229429B2 JP 52017698 A JP52017698 A JP 52017698A JP 1769877 A JP1769877 A JP 1769877A JP S6229429 B2 JPS6229429 B2 JP S6229429B2
- Authority
- JP
- Japan
- Prior art keywords
- amino
- benzimidazole
- formula
- dimethylaminosulfonyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 sulfonylbenzimidazole compound Chemical class 0.000 claims description 30
- 150000001875 compounds Chemical class 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000001118 alkylidene group Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- DZKPMPYJTZYPRR-UHFFFAOYSA-N 2-amino-n,n-dimethyl-6-(1-phenylethenyl)benzimidazole-1-sulfonamide Chemical compound C1=C2N(S(=O)(=O)N(C)C)C(N)=NC2=CC=C1C(=C)C1=CC=CC=C1 DZKPMPYJTZYPRR-UHFFFAOYSA-N 0.000 claims description 3
- KPPANSOANILCFA-UHFFFAOYSA-N 2-amino-n,n-dimethyl-6-(1-phenylprop-1-enyl)benzimidazole-1-sulfonamide Chemical compound C=1C=C2N=C(N)N(S(=O)(=O)N(C)C)C2=CC=1C(=CC)C1=CC=CC=C1 KPPANSOANILCFA-UHFFFAOYSA-N 0.000 claims description 3
- DWKVLTOYMDHKNI-UHFFFAOYSA-N 2-amino-n,n-dimethyl-6-(2-methyl-1-phenylprop-1-enyl)benzimidazole-1-sulfonamide Chemical compound C1=C2N(S(=O)(=O)N(C)C)C(N)=NC2=CC=C1C(=C(C)C)C1=CC=CC=C1 DWKVLTOYMDHKNI-UHFFFAOYSA-N 0.000 claims description 3
- VCKLCXIHDZFCFS-UHFFFAOYSA-N 6-(1-phenylethenyl)-1-propan-2-ylsulfonylbenzimidazol-2-amine Chemical compound C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C(=C)C1=CC=CC=C1 VCKLCXIHDZFCFS-UHFFFAOYSA-N 0.000 claims description 3
- BFPYUXIFGJJYHU-UHFFFAOYSA-N 6-(1-phenylprop-1-enyl)-1-propan-2-ylsulfonylbenzimidazol-2-amine Chemical compound C=1C=C2N=C(N)N(S(=O)(=O)C(C)C)C2=CC=1C(=CC)C1=CC=CC=C1 BFPYUXIFGJJYHU-UHFFFAOYSA-N 0.000 claims description 3
- 239000007818 Grignard reagent Substances 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 26
- 239000000203 mixture Substances 0.000 description 15
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 241000700605 Viruses Species 0.000 description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 12
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241000709661 Enterovirus Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000921 elemental analysis Methods 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- KHPXETCHASHFOZ-UHFFFAOYSA-N 2-amino-6-benzoyl-n,n-dimethylbenzimidazole-1-sulfonamide Chemical compound C1=C2N(S(=O)(=O)N(C)C)C(N)=NC2=CC=C1C(=O)C1=CC=CC=C1 KHPXETCHASHFOZ-UHFFFAOYSA-N 0.000 description 4
- 241001466953 Echovirus Species 0.000 description 4
- 241000991587 Enterovirus C Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000000474 Poliomyelitis Diseases 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- SXUXQJLILGMLOR-UHFFFAOYSA-N (2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-phenylmethanone Chemical compound C1=C2N(S(=O)(=O)C(C)C)C(N)=NC2=CC=C1C(=O)C1=CC=CC=C1 SXUXQJLILGMLOR-UHFFFAOYSA-N 0.000 description 2
- GOGOLGZEKMUVTF-UHFFFAOYSA-N 1-(2-amino-3-propan-2-ylsulfonylbenzimidazol-5-yl)-1-phenylpentan-1-ol Chemical compound CCCCC(O)(C1=CC=CC=C1)C1=CC=C2N=C(N)N(C2=C1)S(=O)(=O)C(C)C GOGOLGZEKMUVTF-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 241000710185 Mengo virus Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BKYIGNVGWWWOOW-UHFFFAOYSA-N 2-amino-6-(1-hydroxy-1-phenylethyl)-n,n-dimethylbenzimidazole-1-sulfonamide Chemical compound C1=C2N(S(=O)(=O)N(C)C)C(N)=NC2=CC=C1C(C)(O)C1=CC=CC=C1 BKYIGNVGWWWOOW-UHFFFAOYSA-N 0.000 description 1
- HJOOHTAHIKWRGA-UHFFFAOYSA-N 2-amino-6-(1-hydroxy-2-methyl-1-phenylpropyl)-n,n-dimethylbenzimidazole-1-sulfonamide Chemical compound C=1C=C2N=C(N)N(S(=O)(=O)N(C)C)C2=CC=1C(O)(C(C)C)C1=CC=CC=C1 HJOOHTAHIKWRGA-UHFFFAOYSA-N 0.000 description 1
- JBAOXNRYELBOKN-UHFFFAOYSA-N 2-amino-n,n-dimethylbenzimidazole-1-sulfonamide Chemical compound C1=CC=C2N(S(=O)(=O)N(C)C)C(N)=NC2=C1 JBAOXNRYELBOKN-UHFFFAOYSA-N 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- IYUBCLHILARKQB-UHFFFAOYSA-N 2-sulfonylbenzimidazole Chemical class C1=CC=CC2=NC(=S(=O)=O)N=C21 IYUBCLHILARKQB-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010047482 Viral upper respiratory tract infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- MYTMXVHNEWBFAL-UHFFFAOYSA-L dipotassium;carbonate;hydrate Chemical compound O.[K+].[K+].[O-]C([O-])=O MYTMXVHNEWBFAL-UHFFFAOYSA-L 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JISVIRFOSOKJIU-UHFFFAOYSA-N hexylidene Chemical group [CH2+]CCCC[CH-] JISVIRFOSOKJIU-UHFFFAOYSA-N 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- LWLPYZUDBNFNAH-UHFFFAOYSA-M magnesium;butane;bromide Chemical compound [Mg+2].[Br-].CCC[CH2-] LWLPYZUDBNFNAH-UHFFFAOYSA-M 0.000 description 1
- QUXHCILOWRXCEO-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CCC[CH2-] QUXHCILOWRXCEO-UHFFFAOYSA-M 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- YCCXQARVHOPWFJ-UHFFFAOYSA-M magnesium;ethane;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C YCCXQARVHOPWFJ-UHFFFAOYSA-M 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- LVKCSZQWLOVUGB-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].C[CH-]C LVKCSZQWLOVUGB-UHFFFAOYSA-M 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/750,991 US4118742A (en) | 1975-08-28 | 1976-12-15 | Carbonyl-substituted 1-sulfonylbenzimidazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5377062A JPS5377062A (en) | 1978-07-08 |
| JPS6229429B2 true JPS6229429B2 (el) | 1987-06-25 |
Family
ID=25019992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1769877A Granted JPS5377062A (en) | 1976-12-15 | 1977-02-18 | Novel 11sulfonyll5*6**substitutedd benzimidazole |
Country Status (26)
| Country | Link |
|---|---|
| JP (1) | JPS5377062A (el) |
| AR (1) | AR225397A1 (el) |
| AT (1) | AT347937B (el) |
| AU (1) | AU509374B2 (el) |
| BE (1) | BE851630A (el) |
| BG (1) | BG27742A3 (el) |
| CA (1) | CA1079737A (el) |
| CH (1) | CH630368A5 (el) |
| CS (1) | CS190339B2 (el) |
| DD (1) | DD129445A6 (el) |
| DE (1) | DE2706227A1 (el) |
| DK (1) | DK145645C (el) |
| ES (1) | ES456090A1 (el) |
| FR (1) | FR2374311A2 (el) |
| GB (1) | GB1568543A (el) |
| GR (1) | GR66420B (el) |
| HU (1) | HU175361B (el) |
| IE (1) | IE44863B1 (el) |
| IL (1) | IL51445A (el) |
| MX (1) | MX4495E (el) |
| NL (1) | NL187396C (el) |
| PL (1) | PL106887B1 (el) |
| RO (1) | RO71886A (el) |
| SE (2) | SE433351B (el) |
| SU (1) | SU680645A3 (el) |
| ZA (1) | ZA77691B (el) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230044254A (ko) | 2020-07-30 | 2023-04-03 | 다이니폰 인사츠 가부시키가이샤 | 항바이러스성 물품 및 항바이러스성 수지 조성물 |
| KR20230070006A (ko) | 2020-09-18 | 2023-05-19 | 다이니폰 인사츠 가부시키가이샤 | 항바이러스성 물품 및 항바이러스성 수지 조성물 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4420479A (en) * | 1982-04-08 | 1983-12-13 | Eli Lilly And Company | Olefinic benzimidazoles, formulations, and antiviral methods |
| FR2593177B1 (fr) * | 1986-01-20 | 1988-04-01 | Novapharme | Nouveaux benzimidazo |
| US5693661A (en) * | 1995-06-07 | 1997-12-02 | Eli Lilly And Company | Anti-viral compounds |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51125078A (en) * | 1974-07-01 | 1976-11-01 | Lilly Co Eli | Production of substituted 11sulphonylbenzimidazole |
-
1977
- 1977-02-07 ZA ZA00770691A patent/ZA77691B/xx unknown
- 1977-02-07 GR GR52736A patent/GR66420B/el unknown
- 1977-02-08 CA CA271,307A patent/CA1079737A/en not_active Expired
- 1977-02-08 IE IE259/77A patent/IE44863B1/en not_active IP Right Cessation
- 1977-02-09 GB GB5254/77A patent/GB1568543A/en not_active Expired
- 1977-02-14 DE DE19772706227 patent/DE2706227A1/de active Granted
- 1977-02-14 IL IL51445A patent/IL51445A/xx unknown
- 1977-02-17 RO RO7789438A patent/RO71886A/ro unknown
- 1977-02-17 NL NLAANVRAGE7701715,A patent/NL187396C/xx not_active IP Right Cessation
- 1977-02-18 BE BE1007954A patent/BE851630A/xx not_active IP Right Cessation
- 1977-02-18 AU AU22440/77A patent/AU509374B2/en not_active Expired
- 1977-02-18 ES ES456090A patent/ES456090A1/es not_active Expired
- 1977-02-18 HU HU77EI729A patent/HU175361B/hu unknown
- 1977-02-18 BG BG7735460A patent/BG27742A3/xx unknown
- 1977-02-18 CS CS771093A patent/CS190339B2/cs unknown
- 1977-02-18 MX MX775442U patent/MX4495E/es unknown
- 1977-02-18 JP JP1769877A patent/JPS5377062A/ja active Granted
- 1977-02-18 AT AT111277A patent/AT347937B/de not_active IP Right Cessation
- 1977-02-18 DD DD7700197445A patent/DD129445A6/xx unknown
- 1977-02-18 SE SE7701845A patent/SE433351B/xx not_active IP Right Cessation
- 1977-02-18 CH CH207577A patent/CH630368A5/de not_active IP Right Cessation
- 1977-02-18 DK DK73277A patent/DK145645C/da not_active IP Right Cessation
- 1977-02-18 SU SU772452269A patent/SU680645A3/ru active
- 1977-02-18 FR FR7704799A patent/FR2374311A2/fr active Granted
- 1977-02-18 AR AR266611A patent/AR225397A1/es active
- 1977-02-19 PL PL1977196131A patent/PL106887B1/pl unknown
-
1980
- 1980-11-18 SE SE8008090A patent/SE433352B/sv not_active IP Right Cessation
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230044254A (ko) | 2020-07-30 | 2023-04-03 | 다이니폰 인사츠 가부시키가이샤 | 항바이러스성 물품 및 항바이러스성 수지 조성물 |
| KR20230070006A (ko) | 2020-09-18 | 2023-05-19 | 다이니폰 인사츠 가부시키가이샤 | 항바이러스성 물품 및 항바이러스성 수지 조성물 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0329348B1 (en) | 2',3'-Dideoxy-2',2'-difluoronucleosides | |
| FI70699B (fi) | Foerfarande foer framstaellning av antivirala substituerade actofenoner | |
| JPS591712B2 (ja) | １−（２−チエニルスルホニル）ベンゾイミダゾ−ル化合物 | |
| Khaligh et al. | Synthesis and in vitro antibacterial evaluation of novel 4-substituted 1-menthyl-1, 2, 3-triazoles | |
| JPS6229429B2 (el) | ||
| CA2098876A1 (en) | 2'-deoxy-2',2-'difluoro(2,6,8-substituted)purine nucleosides having anti-viral and anti-cancer activity and intermediates | |
| AU2012270310B2 (en) | 1,3-Di-oxo-indene derivative, pharmaceutically acceptable salt or optical isomer thereof, preparation method thereof, and pharmaceutical composition containing same as an antiviral, active ingredient | |
| US5750577A (en) | Chromotropic acid-formaldehyde and 1-naphthol-formaldehyde polymeric compounds | |
| HU204841B (en) | Process for producing medicinal nucleosides and pharmaceutical compositions comprising same | |
| US4327088A (en) | Phosphonooxy- or glycosyloxy-substituted acrylophenones, compositions and uses thereof | |
| Desideri et al. | In vitro evaluation of the anti-picornavirus activities of new synthetic flavonoids | |
| US5439899A (en) | Cosalane and related compounds having activity against aids and aids-related infections | |
| JPS6117828B2 (el) | ||
| JPH07267941A (ja) | ３−アリール−グリシド酸エステル誘導体およびその製造方法 | |
| US3018305A (en) | Alpha-phenylben-zoyl-alpha-arylaminocarbinol derivatives | |
| EP0138272B1 (en) | Diarylindane-1,3-diones, their preparation and use | |
| UA44698C2 (uk) | ФІЗИЧНА ФОРМА (R)-7-АЦЕТИЛ-5-(4-АМІНОФЕНІЛ)-8,9-ДИГІДРО-8-МЕТИЛ-7H-1,3-ДІОКСОЛО[4,5-h][2,3]БЕНЗОДІАЗЕПІНУ, СПОСІБ ЇЇ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЇЇ МІСТИТЬ | |
| US4065570A (en) | Antiviral 5-(substituted benzal) hydantoins | |
| KR810000232B1 (ko) | 1-티아졸리닐-5(6)-치환-벤즈이미다졸 유도체의 제조방법 | |
| US4264617A (en) | Antiviral 5-(substituted benzal) hydantoins | |
| EP0204172B1 (en) | Phenylpyrazine derivatives, processes for preparing them, pharmaceutical composition and use | |
| CA1074803A (en) | 1-thiazolinyl-5(6)-substituted-ben-zimidazoles | |
| WO2007039609A1 (en) | Pyranodibenzofuran derivatives with antifungal and antibacterial activity | |
| US4013770A (en) | Antiviral 5-(substituted benzal) hydantoins | |
| US6071945A (en) | 8H-thieno-[2,3-b]pyrrolizin-8-one compounds |